BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Paragon Bioservices 

801 West Baltimore Street
Suite 401
Baltimore  Maryland  21201  U.S.A.
Phone: 800-545-6569 Fax: 410-605-2028


Paragon Bioservices, Inc. is a contract research and GMP manufacturing organization (CRO, CDMO, CMO) that is focused on the development and manufacturing of biopharmaceuticals—either for research purposes or clinical trials. Working as an outsourcing partner and with a long-standing tradition of quality and service, Paragon expands the capabilities of pharmaceutical companies, biotechnology companies and federal agencies involved in the development of Monoclonal Antibodies, Therapeutic Proteins, Vaccines (VLPs) and Stem Cell-Based Therapeutics.

Industry trends and national imperatives include active consolidation in pharmaceutical companies, the advent of virtual biotechnology companies and the need for national preparedness. All of these continue to fuel the need for outsourcing—an all-encompassing practice that, today, includes the entire drug development paradigm: from the discovery bench through process development to GMP manufacturing of drug products for clinical trials. Therefore, Paragon’s corporate strategy is to provide better integration of our offerings to meet the “programmatic outsourcing needs” of our clients.

Our strategy is also to identify niche opportunities and to become the best organization to go to for R&D services and GMP manufacturing of vaccines-VLPs, monoclonal antibodies and stem cell technologies. In addition, we will continue to build infrastructure—while protecting our clients’ intellectual property through domestic R&D and manufacturing.

Founded in 1990, Paragon Bioservices is located at the University of Maryland BioPark in Baltimore. The state of Maryland is one of the best-recognized epicenters of biotechnology in the the world today—as well as home to The FDA, USDA, NIH, NIST, National Cancer Institute and a wealth of major universities. Baltimore itself is home to the world-renowned Johns Hopkins and The University of Maryland School of Medicine. Having access to these institutions—for expertise, consultation, sophisticated analytics, and a vast source of talented personnel—enhances the value of our CMO services and makes Paragon unique among its peers. Maryland is also home to hundreds of biotechnology companies that include AstraZeneca/MedImmune and Human Genome Sciences.

Paragon is focused on continuing to deliver research-grade proteins, process development services, GMP manufacturing (both microbial and mammalian platforms) and cell therapies for Phase I/II clinical trials. Our focus on biologics and efficient integration of single-use technologies allows us to keep our overhead low (as compared to other CMOs, who also provide Phase III and commercial manufacturing). We are agile, creative in problem-solving, flexible, and able to quickly engage additional shifts or added staff—in order to meet aggressive timelines.

Paragon’s business model relies on three independent revenue sources: preclinical services, GMP manufacturing and government contracting—our client base is distributed among pharmaceutical and biotechnology companies (75%) and federal agenices (25%).

Paragon is financially stable and it is presently in the midst of an expansion. Upon completion in 4Q11, the facility will have a total of 52,000 sq ft of state-of-the-art laboratories and manufacturing suites.

Key management listings
• Marco A. Chacon, PhD – President & CEO
• Robert Eberwein – Senior Vice President, GMP Operations
• Vadim Klyushinichenko – Vice President, Preclinical Services & Process Development
• Ronald A.J. Wilson - CFO

Company You Tube Video.

 Key Statistics

Ownership: Private

Web Site: Paragon Bioservices

 Company News
Paragon Bioservices Wins CMO Leadership Awards -- Life Science Leader Magazine Recognizes Paragon Fourth Year In A Row 1/28/2015 10:55:13 AM
Paragon Bioservices Announces Management Team Additions 1/26/2015 10:50:33 AM
Paragon Bioservices Wins NIH Contract For Design & Scale-Up Manufacturing Of rhE -Selectin Protein 11/25/2014 9:24:16 AM
Paragon Bioservices Grabs $13 Million 10/28/2014 6:15:21 AM
Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of Its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of Its Anthrax Vaccine 11/5/2013 9:29:44 AM
Paragon Bioservices Wins CMO Leadership Awards for Third Consecutive Year 9/10/2013 9:39:02 AM
MaxCyte, Inc.® VLX™ and STX™ Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing 1/29/2013 9:45:31 AM
Paragon Bioservices Wins the 2012 CMO Leadership Award 8/2/2012 11:14:50 AM
Paragon Bioservices Awarded Multi-Million Dollar DoD Contract for Filovirus Vaccine Development and Manufacturing 1/18/2012 9:51:40 AM
Paragon Bioservices Appoints Dr. Vadim Klyushnichenko as Vice President of Preclinical Services and Process Development 7/20/2011 11:16:08 AM